Aardvark Therapeutics (AARD) Competitors

$4.54 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$4.72 +0.19 (+4.07%)

As of 05/22/2026 07:05 PM Eastern

AARD vs. PRME, TECX, AVTX, ANL, and IMMX

Should you buy Aardvark Therapeutics stock or one of its competitors? MarketBeat compares Aardvark Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aardvark Therapeutics include Prime Medicine (PRME), Tectonic Therapeutic (TECX), Avalo Therapeutics (AVTX), Adlai Nortye (ANL), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry.

How does Aardvark Therapeutics compare to Prime Medicine?

Aardvark Therapeutics (NASDAQ:AARD) and Prime Medicine (NASDAQ:PRME) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Aardvark Therapeutics presently has a consensus price target of $19.70, suggesting a potential upside of 333.92%. Prime Medicine has a consensus price target of $7.65, suggesting a potential upside of 157.58%. Given Aardvark Therapeutics' higher probable upside, equities analysts clearly believe Aardvark Therapeutics is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aardvark Therapeutics has a beta of 5.11, meaning that its share price is 411% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market.

Aardvark Therapeutics has higher earnings, but lower revenue than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Prime Medicine	$4.63M	115.86	-$201.14M	-$1.23	N/A

Aardvark Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Aardvark Therapeutics' return on equity of -61.71% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

70.4% of Prime Medicine shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Aardvark Therapeutics had 3 more articles in the media than Prime Medicine. MarketBeat recorded 4 mentions for Aardvark Therapeutics and 1 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.00 beat Aardvark Therapeutics' score of -0.14 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aardvark Therapeutics beats Prime Medicine on 9 of the 15 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Tectonic Therapeutic currently has a consensus price target of $79.83, suggesting a potential upside of 174.15%. Aardvark Therapeutics has a consensus price target of $19.70, suggesting a potential upside of 333.92%. Given Aardvark Therapeutics' higher possible upside, analysts clearly believe Aardvark Therapeutics is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Tectonic Therapeutic's return on equity of -32.33% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

In the previous week, Aardvark Therapeutics had 2 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 4 mentions for Aardvark Therapeutics and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.00 beat Aardvark Therapeutics' score of -0.14 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aardvark Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

62.6% of Tectonic Therapeutic shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tectonic Therapeutic has a beta of 3.27, suggesting that its share price is 227% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 5.11, suggesting that its share price is 411% more volatile than the broader market.

Summary

Aardvark Therapeutics beats Tectonic Therapeutic on 7 of the 13 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Avalo Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Aardvark Therapeutics currently has a consensus price target of $19.70, indicating a potential upside of 333.92%. Avalo Therapeutics has a consensus price target of $48.13, indicating a potential upside of 194.34%. Given Aardvark Therapeutics' higher probable upside, research analysts clearly believe Aardvark Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Aardvark Therapeutics has a beta of 5.11, meaning that its share price is 411% more volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Aardvark Therapeutics has higher earnings, but lower revenue than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Avalo Therapeutics	$60K	14,325.33	-$78.26M	-$5.46	N/A

Aardvark Therapeutics' return on equity of -61.71% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Avalo Therapeutics	N/A	-97.54%	-72.42%

In the previous week, Avalo Therapeutics had 9 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 13 mentions for Avalo Therapeutics and 4 mentions for Aardvark Therapeutics. Avalo Therapeutics' average media sentiment score of 0.98 beat Aardvark Therapeutics' score of -0.14 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

87.1% of Avalo Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Aardvark Therapeutics beats Avalo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Adlai Nortye?

Aardvark Therapeutics (NASDAQ:AARD) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

35.2% of Adlai Nortye shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aardvark Therapeutics presently has a consensus target price of $19.70, indicating a potential upside of 333.92%. Adlai Nortye has a consensus target price of $21.67, indicating a potential upside of 81.77%. Given Aardvark Therapeutics' higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Adlai Nortye's return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Adlai Nortye	N/A	N/A	N/A

In the previous week, Aardvark Therapeutics had 3 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for Aardvark Therapeutics and 1 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.00 beat Aardvark Therapeutics' score of -0.14 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
Adlai Nortye	Neutral

Aardvark Therapeutics has a beta of 5.11, indicating that its share price is 411% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Adlai Nortye has higher revenue and earnings than Aardvark Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Adlai Nortye	$5M	95.36	-$35.53M	N/A	N/A

Summary

Adlai Nortye beats Aardvark Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Immix Biopharma has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 5.11, meaning that its share price is 411% more volatile than the broader market.

11.3% of Immix Biopharma shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Immix Biopharma is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Immix Biopharma currently has a consensus price target of $19.50, indicating a potential upside of 122.10%. Aardvark Therapeutics has a consensus price target of $19.70, indicating a potential upside of 333.92%. Given Aardvark Therapeutics' higher possible upside, analysts clearly believe Aardvark Therapeutics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Aardvark Therapeutics' return on equity of -61.71% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

In the previous week, Immix Biopharma had 3 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 7 mentions for Immix Biopharma and 4 mentions for Aardvark Therapeutics. Immix Biopharma's average media sentiment score of 0.55 beat Aardvark Therapeutics' score of -0.14 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aardvark Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Immix Biopharma and Aardvark Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Aardvark Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AARD vs. The Competition

Export

Metric	Aardvark Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$99.04M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-1.41	18.74	21.21	25.65
Price / Sales	N/A	323.98	554.38	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	1.14	7.09	10.37	7.14
Net Income	-$57.59M	$24.45M	$3.57B	$335.98M
7 Day Performance	3.89%	6.38%	6.40%	4.15%
1 Month Performance	-15.77%	2.43%	3.53%	2.54%
1 Year Performance	-56.76%	62.98%	34.04%	35.06%

Aardvark Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
AARD Aardvark Therapeutics	3.0503 of 5 stars	$4.54 flat	$19.70 +333.9%	-56.8%	$99.04M	N/A	N/A	18
PRME Prime Medicine	1.8607 of 5 stars	$2.93 -6.4%	$7.38 +151.7%	N/A	$565.33M	$4.03M	N/A	N/A
TECX Tectonic Therapeutic	1.6701 of 5 stars	$27.89 -6.4%	$79.83 +186.2%	+34.5%	$562.30M	N/A	N/A	120
AVTX Avalo Therapeutics	3.4674 of 5 stars	$17.74 -6.7%	$48.13 +171.3%	+336.0%	$557.49M	$59K	N/A	40
ANL Adlai Nortye	1.6819 of 5 stars	$13.51 -2.5%	$21.67 +60.4%	+544.3%	$554.40M	$5M	N/A	127

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AARD) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aardvark Therapeutics (AARD) Competitors

AARD vs. PRME, TECX, AVTX, ANL, and IMMX

How does Aardvark Therapeutics compare to Prime Medicine?

Summary

How does Aardvark Therapeutics compare to Tectonic Therapeutic?

Summary

How does Aardvark Therapeutics compare to Avalo Therapeutics?

Summary

How does Aardvark Therapeutics compare to Adlai Nortye?

Summary

How does Aardvark Therapeutics compare to Immix Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aardvark Therapeutics (AARD) Competitors

AARD vs. PRME, TECX, AVTX, ANL, and IMMX

How does Aardvark Therapeutics compare to Prime Medicine?

Do analysts rate AARD or PRME?

Which has more volatility and risk, AARD or PRME?

Which has stronger earnings & valuation, AARD or PRME?

Is AARD or PRME more profitable?

Do institutionals and insiders hold more shares of AARD or PRME?

Does the media favor AARD or PRME?

Summary

How does Aardvark Therapeutics compare to Tectonic Therapeutic?

Do analysts rate TECX or AARD?

Is TECX or AARD more profitable?

Does the media prefer TECX or AARD?

Which has stronger earnings and valuation, TECX or AARD?

Do institutionals and insiders have more ownership in TECX or AARD?

Which has more risk and volatility, TECX or AARD?

Summary

How does Aardvark Therapeutics compare to Avalo Therapeutics?

Do analysts rate AARD or AVTX?

Which has more volatility and risk, AARD or AVTX?

Which has stronger earnings and valuation, AARD or AVTX?

Is AARD or AVTX more profitable?

Does the media refer more to AARD or AVTX?

Do institutionals & insiders believe in AARD or AVTX?

Summary

How does Aardvark Therapeutics compare to Adlai Nortye?

Do insiders & institutionals believe in AARD or ANL?

Do analysts rate AARD or ANL?

Is AARD or ANL more profitable?

Does the media refer more to AARD or ANL?

Which has more volatility & risk, AARD or ANL?

Which has better valuation and earnings, AARD or ANL?

Summary

How does Aardvark Therapeutics compare to Immix Biopharma?

Which has more risk & volatility, IMMX or AARD?

Do institutionals and insiders have more ownership in IMMX or AARD?

Which has preferable valuation and earnings, IMMX or AARD?

Do analysts prefer IMMX or AARD?

Is IMMX or AARD more profitable?

Does the media prefer IMMX or AARD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools